Teva's Gemzar ANDAs Infringe Lilly Patent: Judge

Law360, New York (April 1, 2010, 7:44 PM EDT) -- A federal judge has ruled that Teva Pharmaceuticals USA Inc.'s abbreviated new drug applications for Gemzar infringe an Eli Lilly & Co. patent, enjoining the generics maker from introducing its own version of the cancer drug until at least November.

Judge Sarah Evans Barker of the U.S. District Court for the Southern District of Indiana issued the ruling Wednesday, preventing Teva from manufacturing its generic version until Lilly's patent expires Nov. 15.

Two patents were at issue in the case — one for the compounds contained...
To view the full article, register now.